Dosing regiments of celgosivir for the treatment of dengue

Patent metadata

Field	Value
Publication number	US-10517854-B2
Application number	US-201715706845-A
Country	US
Kind code	B2
Filing date	Sep 18, 2017
Priority date	Mar 15, 2013
Publication date	Dec 31, 2019
Grant date	Dec 31, 2019

Abstract

Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV 1-4 viral infections.

First claim

What is claimed is:

1. A method of treating a dengue virus (DENV) infection in a human subject, comprising:
a) administering to the human subject an initial dose of about 100 to about 400 mg of a compound of Formula (II), or a pharmaceutical composition comprising a compound of Formula (II), within from about onset of fever to about 72 hours of fever onset due to dengue infection; and
b) administering to the human subject a dose of about 150 to about 400 mg of a compound of Formula (II), or a pharmaceutical composition comprising a compound of Formula (II), at intervals of about 24 hours until there is an improvement in the infection or between from about 1 day to about 10 days, Formula (II) having the following structure,

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein dengue viral infection comprises at least one dengue virus selected from DENV1, DENV2, DENV3 and DENV4.

3. The method of claim 1 , wherein the dengue viral infection is secondary dengue infection.

4. The method of claim 1 , wherein the compound, or the pharmaceutical composition, is administered intravenously, orally, rectally, or sublingually.

5. The method of claim 1 , wherein the human subject is administered an initial dose of 300 mg and a dose of 300 mg is thereafter administered to the human subject about every 24 hours for about 1 day, about 2 days, or about 5 days.

6. The method of claim 1 , wherein the human subject is administered an initial dose of 150 mg and a dose of 150 mg is thereafter administered to the human subject about every 24 hours for about 1 day, about 2 days, or about 5 days.

7. The method of claim 1 , wherein the human subject is administered an initial dose of 400 mg and a dose of 400 mg is thereafter administered to the human subject about every 24 hours for about 1 day, about 2 days, or about 5 days.

8. The method of claim 1 , wherein the human subject is administered an initial dose of 300 mg and a dose of 150 mg is thereafter administered to the human subject about every 24 hours for about 1 day, about 2 days, or about 5 days.

9. The method of claim 1 , wherein the human subject is administered an initial dose of 150 mg and a dose of 200 mg is thereafter administered to the human subject about every 24 hours for about 1 day, about 2 days, or about 5 days.

10. The method of claim 1 , wherein the human subject is administered an initial dose of 200 mg and a dose of 300 mg is thereafter administered to the human subject about every 24 hours for about 1 day, about 2 days, or about 5 days.

11. The method of claim 1 , wherein the human subject is administered an initial dose of 200 mg and a dose of 150 mg is thereafter administered to the human subject about every 24 hours for about 1 day, about 2 days, or about 5 days.

12. The method of claim 1 , wherein the human subject is administered an initial dose of 200 mg and a dose of 200 mg is thereafter administered to the human subject about every 24 hours for about 1 day, about 2 days, or about 5 days.

13. The method of claim 1 , wherein the human subject is administered an initial dose of 150 mg and a dose of 300 mg is thereafter administered to the human subject about every 24 hours for about 1 day, about 2 days, or about 5 days.

14. The method of claim 1 , wherein the human subject is administered an initial dose of 150 mg and a dose of 400 mg is thereafter administered to the human subject about every 24 hours for about 1 day, about 2 days, or about 5 days.

15. The method of claim 1 , wherein the human subject is administered an initial dose of 200 mg and a dose of 400 mg is thereafter administered to the human subject about every 24 hours for about 1 day, about 2 days, or about 5 days.

16. The method of claim 1 , wherein the human subject is administered an initial dose of 300 mg and a dose of 200 mg is thereafter administered to the human subject about every 24 hours for about 1 day, about 2 days, or about 5 days.

17. The method of claim 1 , wherein the human subject is administered an initial dose of 300 mg and a dose of 400 mg is thereafter administered to the human subject about every 24 hours for about 1 day, about 2 days, or about 5 days.

18. The method of claim 1 , wherein the human subject is administered an initial dose of 400 mg and a dose of 150 mg is thereafter administered to the human subject about every 24 hours for about 1 day, about 2 days, or about 5 days.

19. The method of claim 1 , wherein the human subject is administered an initial dose of 400 mg and a dose of 200 mg is thereafter administered to the human subject about every 24 hours for about 1 day, about 2 days, or about 5 days.

20. The method of claim 1 , wherein the human subject is administered an initial dose of 400 mg and a dose of 300 mg is thereafter administered to the human subject about every 24 hours for about 1 day, about 2 days, or about 5 days.

Assignees

• 60 Degrees Pharmaceuticals Llc
• Nat Univ Singapore
• Singapore Health Serv Pte Ltd

Inventors

• Dow Geoffrey S
• Vasudevan Subhash
• Reid Mark
• Morrish Glynn
• Sung Cynthia
• Rathore Abhay
• Watanabe Satoru
• Ooi Eng Eong
• Low Jenny

Classifications

• A61P31/14

  for RNA viruses · CPC title

• A61K31/437 Primary

  the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline · CPC title

• Y02A50/385

  Cross-Sectional Technologies · mapped topic

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title